Custom-Made vaccine targets pancreatic cancer in early human test
NCT ID NCT05111353
First seen Jun 25, 2026 · Last updated Jun 27, 2026 · Updated 1 time
Summary
This phase 1 trial tested a personalized vaccine made from each patient's unique cancer mutations (neoantigens) combined with an immune booster (poly-ICLC) in 33 people with pancreatic cancer. The vaccine was given after standard chemotherapy, either before or after surgery. The main goal was to check safety and see if the vaccine could trigger an immune response against the cancer.
What this could mean
Our plain-language read of the trial. This is informational only — not medical advice or a prediction.
Active substance
personalized neoantigen synthetic long peptide vaccine plus poly-ICLC (Hiltonol)
What this could lead to
If successful, this could pave the way for a new personalized vaccine approach to help the immune system fight pancreatic cancer after standard chemotherapy.
What could go wrong
This is a very early phase 1 trial with only 33 participants, so safety and immune response are the main goals—not yet proof of effectiveness. The vaccine is custom-made for each patient, which limits scalability and may not work for everyone.
Disclaimer
Read more
Show less
This is a summary of
the original study
.
Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
This is a summary of the original study . Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for PANCREATIC CANCER are added.
By submitting, you agree to our Terms of use
Conditions
The condition(s) this trial relates to.
As listed by the trial registrant
The condition terms exactly as the trial's registrant entered them.
Contacts and locations
Show contact details
Enter your email to view the contact information for this study.
By submitting, you agree to our Terms of use
Locations
-
Washington University School of Medicine
St Louis, Missouri, 63110, United States